Neonatal Jaundice

Introduction and Definition of Neonatal Jaundice

Neonatal jaundice refers to the yellowish discoloration of the skin and sclera in a newborn infant. This condition results from the accumulation of bilirubin, a yellow pigment produced during the normal breakdown of red blood cells. While older children and adults process bilirubin efficiently through the liver, newborns often experience a temporary buildup due to immature hepatic function. It stands as one of the most frequent clinical conditions encountered in neonatal wards across Nigerian hospitals, prompting routine screening for every newborn before discharge.

Bilirubin Metabolism and Physiology in the Newborn

The journey of bilirubin begins with the breakdown of fetal erythrocytes. When red blood cells break down, they release hemoglobin, which splits into heme and globin. Heme is converted into biliverdin and then into unconjugated bilirubin. Because unconjugated bilirubin is fat-soluble and insoluble in water, it binds to serum albumin for transport to the liver. Inside the liver hepatocytes, the enzyme glucuronyl transferase attaches sugar molecules to bilirubin, turning it into conjugated bilirubin. This water-soluble form travels through the biliary system into the gut. Intestinal bacteria then convert it to urobilinogen for excretion in stool and urine. Newborns possess a higher red blood cell mass with a shorter lifespan, producing more bilirubin than an adult liver can instantly handle.

Pathophysiology: Physiological versus Pathological Jaundice

Differentiating between harmless newborn transition and dangerous disease states is a core nursing competency.

• Physiological Jaundice: Appears after 24 hours of life, peaks by day three to five, and resolves within two weeks. It stems from normal newborn red blood cell breakdown and immature liver clearance.
• Pathological Jaundice: Appears within the first 24 hours of life, exhibits rapid bilirubin rise, and persists beyond two weeks. It points to underlying disorders like blood group incompatibilities, severe infection, or G6PD deficiency.

Etiology and Risk Factors in the Nigerian Context

Several local and genetic factors influence the prevalence and severity of neonatal jaundice in Nigeria.

• Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: An inherited enzyme defect highly prevalent in sub-Saharan Africa that triggers rapid red cell hemolysis when exposed to certain triggers like menthol or malaria drugs.
• ABO and Rhesus Incompatibility: Maternal-fetal blood group mismatches causing aggressive immune-mediated destruction of fetal red blood cells.
• Neonatal Sepsis: Bacterial infections common in resource-constrained settings that impair liver function and accelerate hemolysis.
• Prematurity: Preterm infants have poorly developed liver enzyme systems and fragile red cells.

Clinical Assessment and Physical Examination

Assessment begins with visual inspection in a well-lit room, preferably under natural daylight. The nurse uses finger pressure on the infant's skin to blanch the area and observe the underlying color. Jaundice progresses in a cephalocaudal direction—starting at the face and moving downward to the chest, abdomen, and soles.

Visual estimation alone is notoriously unreliable, especially in babies with darker skin tones, making objective testing mandatory.

Diagnostic Investigations and Monitoring

Accurate management requires laboratory confirmation of total serum bilirubin (TSB). Blood samples are collected via heel prick or venipuncture. Transcutaneous bilirubinometers offer a non-invasive screening alternative, though confirmatory serum testing remains the gold standard when levels are high or treatment is considered. Additional baseline investigations include blood grouping and Rh typing for both mother and infant, a direct Coombs test to detect immune-mediated hemolysis, packed cell volume, and G6PD screening.

Medical Management and Treatment Modalities

Treatment aims to lower unconjugated bilirubin levels and prevent neurotoxicity.

1. Phototherapy: The primary intervention. Exposing the undressed infant to special blue-green light converts unconjugated bilirubin in the skin into water-soluble isomers that are easily excreted in urine and stool.
2. Exchange Transfusion: Reserved for severe cases where phototherapy fails or rapid neurotoxicity threatens. Patient blood is incrementally withdrawn and replaced with donor blood.
3. Hydration Support: Ensuring adequate breast milk or formula intake promotes bowel movements to clear conjugated pigments.

Complications including Acute Bilirubin Encephalopathy and Kernicterus

When unconjugated bilirubin crosses the blood-brain barrier, it deposits in basal ganglia and brainstem nuclei, causing devastating neurological damage.

• Acute Bilirubin Encephalopathy (ABE): The acute clinical manifestation of bilirubin toxicity in the brain. Early signs include lethargy, poor sucking reflex, and hypotonia. If untreated, it progresses to high-pitched crying, retrocollis (backward arching of the neck), and opisthotonos (rigid body arching).
• Kernicterus: The permanent, chronic neurological sequelae of ABE, characterized by choreoathetoid cerebral palsy, sensorineural hearing loss, and upward gaze abnormalities.

Nursing Care Plan and Parental Education

Comprehensive nursing care safeguards the infant during treatment and supports the family through a stressful hospital admission.

• Phototherapy Safety: Ensure eyes are covered securely with opaque patches to prevent retinal damage, maintain optimal incubator or body temperature, and monitor fluid balance since radiant warmers increase insensible water loss.
• Skin and Excreta Care: Frequently change diapers and apply barrier cream, as phototherapy often causes loose, green stools.
• Emotional Support and Education: Reassure anxious parents, explain equipment usage clearly, and teach them to recognize warning signs like worsening yellow color or lethargy after discharge.